BIIB

‘s Golden Touch Curiosity Stream $CURI

by

For trade details click on this link to the trades CuriosityStream Inc. up 38.44% KULICKE & SOFFA INDUSTRIES INC up 11.98% GREENBRIER COMPANIES INC up 5.53 Apollo Endosurgery Inc. up 5.51% BIOGEN Inc up 4.13% UGI CORP up 3.79% Adtalem Global Education Inc. up 5.51% CALIX INC up2.94% Dun & Bradstreet Holdings Inc. up 0.9% CROWN CASTLE INTERNATIONAL CORP  up 0.88% UNITEDHEALTH GROUP INC down -1.33% Anthem Inc.  down -1.81% All it takes is a $million dollars sometime and a track record behind it.  Founder John Hendricks purchased 74,000 shares of Curiosity Stream at $13.50 on 2-8. By the end … Read more

Fool Me Once, Shame on You, Fool Me Twice, Shame on Me-Insider Buying Week Ending 12/4/20

by

For trade details click on this link to the trades   ATLAS TECHNICAL CONSULTANTS Inc up 28.91% Organogenesis Holdings Inc. up 3.04% Kraft Heinz Co up 2.71% MARAVAI LIFESCIENCES HOLDINGS Inc up 2.52% BIOGEN Inc up 1.89% American Homes 4 Rent up 1.89% HORMEL FOODS CORP up 0.87% HC2 HOLDINGS Inc down -1.15% CNX Resources Corp down-1.27% Black Knight Inc.  down -1.27% Biogen is our pick of the week.  Biogen made a fresh push to get aducanumab approved after the early read on the trials was discouring. The stock ran up significantly on the potential for the first drug to … Read more

We took money off the table today in a bad tape with a good trade on Biogen

by

Biogen spiked handsomely today and we took money off the table in a bad tape. We wrote on May 4th, that we were particularly excited about Biogen. Two insiders had bought material amounts of stock Biogen when the stock lost more than a quarter of its value during premarket trading Thursday morning after the company announced it would discontinue trials of its Alzheimer’s disease drug.   CEO Vounatsos increased his holdings by 21.6% purchasing 4,351 shares at $231.48.  Longtime board member and biotech guru hedge fund manager, Alexander Denner laid down a cool $27.2 million increasing his holdings by 22.1%. Anxiety … Read more

No Time For Heroes

by

  The Insiders Fund, went 80% to cash last Wednesday in part market-driven, in part disillusioned with the likelihood of a China trade deal.  The Fund had a great run up this year, over 24%, and now many stocks appear grossly over-valued.  The “cloud” software stocks seem to have nothing but clouds themselves supporting their valuations.  To top it off Uber went public at an $85 billion dollar valuation. This is for a company that has never made money, maybe never will as the drivers are estimated to be making less than minimum wage after factoring the cost of their … Read more

Notable Insider Buys and Sells Week Ending May 3, 2019 or Sell in May, Go Away

by

  Several new buys this week signaled a return to animal spirits for a small group.  The majority of corporate America beat the drum beat, sell in May, Go Away. The market marched to a new high but not every stock participated. These buys represent value in an overvalued market, perhaps one long in the tooth.  We don’t aim to predict tops or bottoms but when insiders buy large amounts of their own company’s stock, they do it for one reason; to make money. We are highlighting notable buys over $200,000 as this represents something more than window dressing. Buys … Read more

Biogen is a Table Thumping Buy $BIIB

by

            Several new buys this week signaled a return to animal spirits. We are particularly excited about Biogen. Biogen (BIIB) had a double whammy over the last two weeks. Two insiders bought material amounts of stock Biogen when the stock lost more than a quarter of its value during premarket trading Thursday morning after the company announced it would discontinue trials of its Alzheimer’s disease drug.   CEO Vounatsos increased his holdings by 21.6% purchasing 4,351 shares at $231.48.  Longtime board member and biotech guru hedge fund manager, Alexander Denner laid down a cool $27.2 million … Read more

Top Stocks Insiders are Buying and Selling Week ending 12-1-17

by

$PSEC,$BIIB,$TEP,$MDCO,$ETM,$MELI,$ORLY,$LOXO,$SCHW,$INTU,$DATA,$HDP,$PEN,$CBG,$SHAK,$QLYS,$RJF,$DE,$PANW In this report we examine stocks that C-level officers and directors  bought and sold ending the week of September 22nd, 2017.  Insiders sell stock for a variety of reasons but they generally buy for just one, to make money.  We only look at material amounts of money, $100k or more, as anything less could be window dressing.  The bar is different on selling as the natural state of management is to be sellers.  Most companies provide significant amounts of their compensation packages as stock. Therefore we analyze selling for unusual patterns; such as insider selling 25% or more of … Read more

Pullback in pharma has created a compelling buying opportunity

by

The fundamentals are good for the health care sector in general.  Recent news articles on drug pricing/gouging are not likely to effect meaningful change for the overall group dynamics in my opinion or that any changes may be long time in coming and tempered far below market expectations. It’s true that it may compress multiple prices for a while as Evercore #1 ranked biotech analyst Mark Schoenebaum said on CNBC today but I agree with him, its really about innovation.  His favorite picks are Gilead GILD and maintains a price target of $115 on the stock.  I am not as enthusiastic … Read more